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Abstract: Taurine is a sulfur containing nutrient that has been shown to protect against oxidative
stress, which has been implicated in the pathophysiology leading to late graft failure after renal
transplantation. We prospectively investigated whether high urinary taurine excretion, reflecting
high taurine intake, is associated with low risk for development of late graft failure in renal transplant
recipients (RTR). Urinary taurine excretion was measured in a longitudinal cohort of 678 stable RTR.
Prospective associations were assessed using Cox regression analyses. Graft failure was defined as
the start of dialysis or re-transplantation. In RTR (58% male, 53 ± 13 years old, estimated glomerular
filtration rate (eGFR) 45 ± 19 mL/min/1.73 m2), urinary taurine excretion (533 (210–946) µmol/24 h)
was significantly associated with serum free sulfhydryl groups (β = 0.126; P = 0.001). During median
follow-up for 5.3 (4.5–6.0) years, 83 (12%) patients developed graft failure. In Cox regression analyses,
urinary taurine excretion was inversely associated with graft failure (hazard ratio: 0.74 (0.67–0.82);
P < 0.001). This association remained significant independent of potential confounders. High urinary
taurine excretion is associated with low risk of late graft failure in RTR. Therefore, increasing taurine
intake may potentially support graft survival in RTR. Further studies are warranted to determine the
underlying mechanisms and the potential of taurine supplementation.
Keywords: renal transplant recipients; taurine; taurine excretion; graft survival
1. Introduction
Globally, renal transplantation becomes more prevalent each year [1], and renal transplantation
is the preferred treatment for end-stage renal disease. However, donor kidneys remain sparse and
patients often spend years on waiting lists or depend on a sacrifice by a family member or friend in
Nutrients 2019, 11, 2212; doi:10.3390/nu11092212 www.mdpi.com/journal/nutrients
Nutrients 2019, 11, 2212 2 of 18
the form of a living donation. Therefore, protection of donated kidneys and improving long-term
graft survival is a major clinical, as well as ethical, necessity. Due to improvements in surgical
techniques, immunosuppressant drugs and postoperative care, the one-year survival rate has steadily
improved, but late graft failure occurring beyond the first year after transplantation has not decreased
substantially in the last decades [2]. Though the exact mechanisms leading to late graft failure are not
fully understood, oxidative stress has been implicated [3–6].
Taurine is an amino sulfonic acid found in high concentrations in many cells, where it is implicated
in numerous physiological functions. In some species, e.g., cats, taurine is an essential nutrient, but in
humans, it is considered a conditionally essential nutrient [7–9]. While taurine can be synthesized
endogenously, humans primarily depend on their diet for taurine, where it is mostly found in seafood
and meat [10,11]. Although taurine fulfills a wide array of function, its cytoprotective actions have
received the most attention [7,12–14]. Taurine has been demonstrated to have renoprotective effects in
several animal studies [15–18]. In rats, preconditioning of donor organs with taurine protected grafts
during transplantation against both cold ischemia and ischemia reperfusion injury [19]. However, the
effects of taurine on long term graft survival in humans are not known. Based on the acknowledged
cytoprotective properties of taurine, we hypothesize that a higher taurine exposure is associated with
improved renal graft survival. Therefore, the primary aim of our study was to investigate whether 24 h
urinary taurine excretion is associated with graft failure in stable outpatient renal transplant recipients.
2. Materials and Methods
2.1. Study Population
This observational prospective study was conducted in a large single center renal transplant
recipients (RTR) cohort, as previously described [20,21]. In short, all adult (≥18 years old) RTR without
known or apparent systemic illnesses (i.e., malignancies, opportunistic infections) who visited the
outpatient clinic of the University Medical Center Groningen between November 2008 and June 2011
were invited to participate in this prospective cohort study. RTR were all transplanted at the University
Medical Center Groningen and had no history of drug or alcohol addiction. Of the 817 initially invited
RTR, 706 (87%) signed written informed consent to participate in this study. We excluded subjects with
missing data on urinary taurine excretion, i.e., 28 cases, from the statistical analyses, which resulted in
678 cases eligible for analyses. To compare urinary taurine excretion of RTR with patients without renal
disease, we included 275 healthy kidney donors of whom biomaterial was collected before kidney
donation. The study protocol was approved by the University Medical Center Groningen institutional
ethical review board (Medical ethical committee 2008/186) and adhered to the Declarations of Helsinki.
2.2. Clinical Parameters
All measurements were performed during a morning visit to the outpatient clinic after an 8-
to 12-h overnight fasting period. Blood pressure was measured (in millimeters of mercury) with a
semiautomatic device (Dinamap 1846; Critikon, Tampa, FL, USA) according to a strict protocol as
previously described [22]. Information on participants’ health status, medical history, and medication
use was obtained from patient records. Information on smoking behavior and alcohol intake was
obtained by using a questionnaire. Participants were classified as current, former, or never smokers.
Alcohol intake was split into no intake, low intake (0–5 g/24 h in females and 0–10 g/24 h in males) and
high intake (>5 g/24 h in females and >10 g/24 h in males). Body weight and height were measured
with participants wearing indoor clothing without shoes. Body mass index (BMI) was calculated as
weight in kilograms divided by height in meters squared and body surface area (BSA) was calculated
using the formula of Du Bois and Du Bois [23]. Diabetes mellitus was diagnosed according to American
Diabetes Association criteria (2017) as having a fasting plasma glucose concentration ≥7.0 mmol/L or
the use of an antidiabetic medication [24,25]. Hypertension was defined as predialysis systolic blood
pressure >140 mmHg and/or diastolic blood pressure >90 mmHg or use of antihypertensive drugs.
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2.3. Dietary Intake
Information on dietary intake was obtained from a validated semiquantitative food-frequency
questionnaire (FFQ), which was linked to the Dutch food composition table (NEVO) to compute the
intake of energy, macronutrients and micronutrients [26]. It was not possible to compute intake of
taurine using the FFQ, because the Dutch food composition table does not contain data on taurine
contents of food items. Because not all participants completed or returned the FFQ, 641 RTR and
183 controls had data available on dietary intake. The FFQ inquired about intakes of 177 food items
during the past month with seasonal variations taken into account. For each item, the frequency
was recorded in times per day, week, or month. The number of servings was expressed in natural
units (e.g., slice of bread or apple) or household measures (e.g., cup or spoon). The questionnaire
was self-administered and filled out at home. Every FFQ was checked for completeness by a trained
researcher, and inconsistent answers were verified with the patients. Validation of the FFQ in RTR was
assessed, as previously reported [27]. Dietary data were converted into daily nutrient intakes with the
use of the Dutch Food Composition Table of 2006 [28]. Dietary intakes were adjusted for total energy
intake (kcal/24 h) according to the residual method [29].
2.4. Laboratory Measurements
All participants were instructed to collect a 24-h urine sample according to a strict protocol at the
day before their visit to the outpatient clinic. Urine was collected under oil and chlorhexidine was
added as an antiseptic agent. Urine taurine concentrations were analyzed by ultra-high performance
liquid chromatography triple quadrupole mass spectrometry analysis (UHPLC-MS/MS). In short,
samples were derivatized using AccQ•Tag derivatization reagent according to the manufacturer’s
protocol (Waters Corporation, Milford, MA, USA) and separated using a Cortecs UPLC C18 (1.6 µm
pore size, 150 × 2.1 mm) analytical column. Taurine was detected using positive-ion electrospray
ionization in multiple reaction monitoring mode, using the following transitions: m/z 295.9 -> 171.0
for taurine and 335 -> 171.0 for the internal standard (13C6, 15N3-histidine). Data were analyzed using
MultiQuant MD 3.0.2 (Sciex). Inter-assay precision was monitored using three urine pool samples.
The inter-assay precisions were 8.5% at 270.4 µmol/L, 9.8% at 594.7 µmol/L and 7.9% at 762.0 µmol/L.
The upper limit of detection was 1200 µmol/L and values above 1200 µmol/L were reported as 1201
µmol/L. Urinary protein concentration was determined by means of the Biuret reaction (MEGA AU 510;
Merck Diagnostica, Darmstadt, Germany). Proteinuria was defined as urinary protein excretion ≥0.5
g/24 h. Upon completion of the 24-h urine collection, fasting venous blood samples anti-coagulated
with lithium-heparin, sodium-fluoride and potassium-ethylenediaminetetraacetic acid (EDTA) were
obtained the following morning. For routine clinical chemistry assays, heparin plasma was analyzed
spectrophotometrically on the same morning using automated and validated routine methods (Roche
Diagnostics, Basel, Switzerland). Fasting glucose was assessed from fluoride plasma on the same
morning on the same equipment. EDTA plasma was separated in small aliquots and stored frozen at
−80◦C for later use. Aliquots of the 24 h urine collection were also stored frozen at −80◦C for later use.
Free sulfhydryl groups in serum were quantified using Ellman’s reagent. Human leukocyte antigen I
(HLA-I) and HLA-II antibodies were quantified using an ELISA (LATM205, One Lambda, Canoga Park,
CA, USA). Urinary inorganic sulfate was measured with a validated ion-chromatography method (type
861; Metrohm, Herisau, Switzerland). Urinary thiosulfate was determined using a validated HPLC
method [20]. Renal function was assessed by the estimated glomerular filtration rate (eGFR) based on
the Chronic Kidney Disease Epidemiology Collaboration Creatinine Cystatin C (CKD-EPI-sCr-CysC)
equation [30].
2.5. Graft Failure
The endpoint of this study was graft failure. Graft failure was defined as re-transplantation or
return to dialysis and was censored for death. The continuous surveillance system of the outpatient
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program ensured that there was up-to-date information on patient status. Endpoints were recorded
until September 2015 by a qualified physician, with no loss to follow-up.
2.6. Statistical Analysis
Data analyses and computations were performed with SPSS 24.0 software (IBM, Armonk, NY, USA),
Stata SE version 15 (StataCorp, College Station, TX, USA), R version 3.5.1 software (The R-Foundation
for Statistical Computing), and GraphPad Prism version 5 (GraphPad Software). Baseline data are
presented as means ± standard deviation for normally distributed data, as medians (interquartile
range) for non-normally distributed data, and as numbers (percentages) for nominal data. A two-sided
P < 0.05 was considered to indicate statistical significance. Differences between RTR and healthy
controls were tested with a t-test for independent samples, the Mann–Whitney U test, or the chi-squared
test. Cross-sectional associations of urinary taurine excretion with baseline variables were studied using
linear regression models. Regression coefficients were given as standardized beta values, the latter
referring to the number of standard deviations a dependent variable changes per standard deviation
increase of the independent variable, thereby allowing for comparison of the strength of the associations
of different variables. Cox regression analyses were employed to investigate the association of urinary
taurine excretion, with graft failure. Secondarily, analyses were also performed for urinary taurine
concentration and urinary taurine/creatinine ratio. Cox regression models were built in a stepwise
fashion to avoid overfitting and to keep the number of predictors in proportion to the number of
events [31]. Adjustments were made for a priori selected variables and for potentially relevant variables
identified using linear regression analyses. A priori selected variables were basic potential confounders
(model 2), cardiovascular risk factors (model 3) and transplantation related factors (model 4). Basic
potential confounders were defined as age, sex, weight, height, eGFR and proteinuria. Cardiovascular
risk factors were defined as total cholesterol, High-density lipoprotein (HDL) cholesterol, triglycerides,
systolic blood pressure, antihypertensive treatment, smoking (current, ex, or never), presence of
diabetes, medical history of coronary intervention, myocardial infarction, cerebrovascular accident
(CVA) and/or transient ischemic attack (TIA). Transplantation related factors were defined as donor
type, total dialysis time, time from transplantation and baseline, cold ischemia time, calcineurin
inhibitor (CNI) usage, proliferation inhibitor usage, and the number of transplantations up to baseline.
Potentially relevant variables were selected if the P value for the association with urinary taurine
excretion (Table 1) was <0.05. In model 5, we adjusted for potentially relevant variables that have not
been adjusted for in previous models. Schoenfeld residuals of urinary taurine excretion, urinary taurine
concentration and urinary taurine/creatinine ratio were checked in R, the assumption of proportional
hazards was not violated for urinary taurine excretion, urinary taurine concentration and the urinary
taurine/creatinine ratio (P = 0.77, P = 0.65 and P = 0.55, respectively). Potential interactions for
the covariates age, sex, body mass index (BMI), hypertension, diabetes, renal function, proteinuria,
smoking status, alcohol intake and time between baseline and transplantation were assessed by
calculating interaction terms. To determine the optimal cut off value (Youden index) of urinary taurine
excretion for prediction of graft failure in RTR, the ‘survivalROC’ package in R was used. To visualize
the continuous associations of urinary taurine excretion, urinary taurine concentration and urinary
taurine/creatinine ratio with graft failure, log2-transformed urinary taurine excretion, urinary taurine
concentration and urinary taurine/creatinine ratio, as continuous variables, were individually plotted
against the risk of graft failure.
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3. Results
3.1. Baseline Characteristics of RTR and Controls
Characteristics of RTR versus controls are shown in supplementary Table S1. For RTR, the
median time between transplantation and baseline measurements was 5.3 (1.8–11.5) years. Urinary
taurine excretion (533 (210–946) µmol/24 h versus 477 (253–943) µmol/24 h; P = 0.92), urinary taurine
concentration (216 (87–415)µmol/L versus 199 (100–394)µmol/L;P= 0.85) and urinary taurine/creatinine
ratio (46 (20–80) µmol/mmol versus 41 (21–66) µmol/mmol; P = 0.21) were similar in RTR and controls,
respectively. The two groups were also similar with respect to age, height and BSA, though RTR had a
higher BMI (26.6 ± 4.8 kg/m2 versus 26.0 ± 3.5 kg/m2; P = 0.02). Men were overrepresented in the RTR
group compared with the control group (58% male versus 47% male; P = 0.002). As anticipated, eGFR
was significantly lower in RTR than in controls (45 ± 19 mL/min/1.73 m2 versus 92 ± 16 mL/min/1.73 m2;
P < 0.001). Animal-based protein intake was similar in RTR and controls (51 ± 13 versus 51 ± 12 g/24 h;
P = 0.98), while energy intake (2172 ± 619 versus 2294 ± 730 kcal/24 h; P = 0.02), total protein intake
(82 ± 12 g/24 h versus 85 ± 15 g/24 h; P = 0.007), plant protein intake (31 ± 6 g/24 h versus 33 ± 8 g/24 h;
P < 0.001), cysteine intake (1187 ± 172 mg/24 h versus 1238 ± 190 mg/24 h; P = 0.001), total fat intake
(88 ± 16 g/24 h versus 94 ± 20 g/24 h; P = 0.001) and total carbohydrate intake (249 ± 63 g/24 h versus
258 ± 49 g/24 h; P = 0.03) were lower in RTR compared to controls.
3.2. Linear Regression
Selected baseline characteristics of RTR and linear regression analysis are shown in Table 1.
Univariate, urinary taurine excretion was positively associated with serum free sulfhydryl groups
(β = 0.249; P < 0.001), urinary taurine concentration (β = 0.962; P < 0.001), urinary taurine/creatinine
ratio (β = 0.969; P < 0.001), male sex (β = 0.374; P < 0.001), never smoking status (β = 0.083; P = 0.04),
weight (β = 0.121; P = 0.002), height (β = 0.266; P < 0.001), BSA (β = 0.196; P < 0.001), use of proliferation
inhibitors (β = 0.095; P = 0.01), prednisolone dosage (β = 0.135; P < 0.001), eGFR (β = 0.252; P < 0.001),
creatinine clearance (β = 0.361; P < 0.001) and urinary excretion of sodium (β = 0.288; P < 0.001),
chloride (β = 0.268; P < 0.001), sulfate (β = 0.324; P < 0.001), thiosulfate (β = 0.285; P < 0.001) and
creatinine (β = 0.397; P < 0.001). In contrast, urinary taurine excretion was inversely associated with
antihypertensive drugs (β = −0.082; P = 0.03), N-terminal pro b-type natriuretic peptide (NT-proBNP)
(β = −0.196; P < 0.001), total cholesterol (β = −0.174; P < 0.001), HDL cholesterol (β = −0.112; P = 0.004),
LDL cholesterol (β = −0.094; P = 0.02), triglycerides (β = −0.168; P < 0.001), use of statins (β = −0.080;
P = 0.04), use of antidiabetic drugs (β = −0.093; P = 0.02), time between baseline and transplantation
(β = −0.169; P < 0.001), HLA-I antibodies (β = −0.110; P = 0.004), HLA-II antibodies (β = −0.133;
P = 0.001), serum creatinine (β = −0.129; P < 0.001) and proteinuria (β = −0.107; P = 0.005). Adjustment
for age, sex and eGFR revealed an association of urinary taurine excretion with past smoking status
(β = −0.087; P = 0.02), polycystic kidney disease (β = 0.081; P = 0.02) and use of calcineurin inhibitors
(β = 0.082; P = 0.02). In addition, adjustment for age, sex and eGFR strengthened the associations of
urinary taurine excretion with urinary taurine/creatinine ratio (β = 0.993; P < 0.001), never smoking
status (β = 0.113; P = 0.002) and time between baseline and transplantation (β = −0.180; P < 0.001). In
contrast, adjustment for age, sex and eGFR somewhat weakened the associations of urinary taurine
excretion with serum free sulfhydryl groups (β = 0.126; P = 0.001), total cholesterol (β = −0.120;
P < 0.001), triglycerides (β = −0.118; P = 0.001), use of antidiabetic drugs (β = −0.079; P = 0.03), eGFR
(β = 244; P < 0.001), creatinine clearance (β = 0.314; P < 0.001), proteinuria (β = −0.086; P = 0.02), and
urinary excretion of sodium (β = 0.179; P < 0.001), chloride (β = 0.151; P < 0.001), sulfate (β = 0.199;
P < 0.001), thiosulfate (β = 0.170; P < 0.001) and creatinine (β = 0.265; emphP < 0.001). The associations
of urinary taurine excretion with weight, height, BSA, use of antihypertensive drugs, NT-proBNP, HDL
cholesterol, LDL cholesterol, use of statins, use of proliferation inhibitors, prednisolone dosage, HLA-I
antibodies, HLA-II antibodies and serum creatinine all disappeared after adjustment for age, sex and
eGFR (all P > 0.05).
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Table 1. Baseline characteristics in 678 renal transplant recipients (RTR) and regression coefficients of the associations with log2 transformed urinary taurine excretion.
Variable RTR Cohort (n = 678) Range
Model 1 Model 2
Std. β P value Std. β P value
Taurine
Urinary taurine excretion, µmol/24 h 533 (210–946) 9–3637
Urinary taurine concentration, µmol/L 216 (87–415) 3–1201 0.962 <0.001 0.953 <0.001
Urinary taurine/creatinine ratio, µmol/mmol 46 (20–80) 1–429 0.969 <0.001 0.993 <0.001
Demographics
Age, years 53 ± 13 18–80 −0.007 0.86 0.019 0.58
Sex, n (% male) 390 (58) −0.374 <0.001 −0.369 <0.001
Smokers, n (%)
Never 265 (42) 0.083 0.04 0.113 0.002
Past 287 (45) −0.071 0.07 −0.087 0.02
Current 82 (13) −0.016 0.68 −0.038 0.29
Alcohol intake a
No alcohol 23 (4) −0.037 0.36 −0.004 0.91
Low intake 400 (65) 0.001 0.98 0.029 0.42
High intake 197 (32) 0.014 0.73 −0.029 0.44
Body composition
Weight, kg 80 ± 17 35–164 0.121 0.002 0.008 0.82
Height, cm 174 ± 10 127–197 0.266 <0.001 0.053 0.26
BMI, kg/m2 26.6 ± 4.8 15.7–45.0 −0.023 0.55 −0.005 0.88
BSA, m2 1.94 ± 0.22 1.09–2.83 0.196 <0.001 0.025 0.54
Primary renal disease, n (%)
Primary glomerulosclerosis 194 (29) −0.020 0.61 −0.051 0.14
Glomerulonephritis 49 (7) 0.009 0.82 0.012 0.73
Tubulointerstitial nephritis 83 (12) −0.023 0.55 −0.014 0.70
Polycystic kidney disease 139 (21) 0.035 0.36 0.081 0.02
Hypo- or dysplasia 28 (4) 0.015 0.70 0.009 0.81
Renovascular disease 38 (6) −0.020 0.61 −0.039 0.26
Diabetes 34 (5) −0.002 0.96 0.004 0.92
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Table 1. Cont.
Variable RTR Cohort (n = 678) Range
Model 1 Model 2
Std. β P value Std. β P value
Cardiovascular history, n (%)
Coronary intervention 68 (10) −0.005 0.90 −0.028 0.44
Myocardial infarction 34 (5) 0.036 0.35 0.031 0.38
CVA and/or TIA 41 (6) −0.038 0.33 −0.012 0.73
Cardiovascular
Systolic blood pressure, mmHg 136 ± 17 88–200 <0.001 1.00 −0.020 0.57
Diastolic blood pressure, mmHg 83 ± 11 50–125 0.043 0.27 −0.016 0.65
Mean arterial pressure, mmHg 107 ± 15 63–167 −0.002 0.95 −0.025 0.48
Pulse pressure, mmHg 54 ± 13 20–114 −0.037 0.34 −0.014 0.70
Heart rate, bpm 68 ± 12 41–122 −0.001 0.98 0.047 0.20
Hypertension, n (%) 275 (41) 0.037 0.33 0.002 0.95
Antihypertensive drugs, n (%) 595 (88) −0.082 0.03 −0.062 0.09
Nt-proBNP, ng/L 247 (105–598) 1–110,000 −0.196 <0.001 −0.029 0.55
Lipids
Total cholesterol, mmol/L 5.1 ± 1.1 2.3–9.7 −0.174 <0.001 −0.120 0.001
HDL cholesterol, mmol/L 1.4 ± 0.5 0.4–3.5 −0.112 0.004 −0.058 0.12
LDL cholesterol, mmol/L 3.0 ± 0.9 0.7–6.6 −0.094 0.02 −0.062 0.08
Triglycerides, mmol/L 1.7 (1.2–2.3) 0.3–8.5 −0.168 <0.001 −0.118 0.001
Statins, n (%) 360 (53) −0.080 0.04 −0.063 0.08
Glucose homeostasis
Glucose, mmol/L 5.3 (4.8–6.1) 2.1–21.7 0.002 0.97 −0.033 0.34
HbA1c, % 5.8 (5.5–6.2) 4.5–11.8 0.003 0.95 −0.019 0.61
Diabetes, n (%) 162 (24) −0.059 0.12 −0.044 0.21
Antidiabetic drugs, n (%) 107 (16) −0.093 0.02 −0.079 0.03
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Table 1. Cont.
Variable RTR Cohort (n = 678) Range
Model 1 Model 2
Std. β P value Std. β P value
Transplantation-related
Dialysis vintage, months 27 (10–52) 0–226 0.009 0.84 0.037 0.34
Time since transplantation, years 5.3 (1.8–11.5) 0.2–39 −0.169 <0.001 −0.180 <0.001
Deceased donor, n (%) 446 (66) 0.055 0.15 0.038 0.30
Cold ischemia time (hours) 15 (3–21) 0–40 −0.049 0.21 −0.028 0.44
Warm ischemia time (minutes) 40 (35–50) 10–128 0.035 0.37 0.024 0.49
Transplantations up to baseline, n (%) −0.051 0.19 −0.018 0.62
1 transplantation 612 (90)
≥2 transplantations 66 (10)
Calcineurin inhibitors, n (%) 381 (56) 0.021 0.59 0.082 0.02
Proliferation inhibitor, n (%) 567 (84) 0.095 0.01 0.054 0.13
Prednisolone dosage, n (%) 0.135 <0.001 0.064 0.07
≤7.5 mg/24 h 275 (41)
>7.5 mg/24 h 403 (59)
HLA antibodies, n (%)
HLA-I 106 (16) −0.110 0.004 −0.026 0.46
HLA-II 114 (17) −0.133 0.001 −0.067 0.06
Renal function
Serum creatinine, µmol/L 124 (99–160) 50–591 −0.129 <0.001 −0.079 0.40
eGFR, ml/min/1.73m2 b 45 ± 19 7–107 0.252 <0.001 0.244 <0.001
Creatinine clearance, ml/min 66 ± 27 12–186 0.361 <0.001 0.314 <0.001
Proteinuria, n (%) 152 (22) −0.107 0.005 −0.086 0.02
Oxidative stress and inflammation
Free sulfhydryl groups (µmol/L) 132 ± 49 10–387 0.249 <0.001 0.126 0.001
hsCRP, mg/L 1.6 (0.7–4.5) 0.1–114 −0.037 0.35 0.006 0.88
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Table 1. Cont.
Variable RTR Cohort (n = 678) Range
Model 1 Model 2
Std. β P value Std. β P value
Urinary excretion
Sodium, mmol/24 h 158 ± 62 24–374 0.288 <0.001 0.179 <0.001
Chloride, mmol/24 h 138 (108–181] 28–391 0.268 <0.001 0.151 <0.001
Sulfate, mmol/24 h 17.6 ± 6.4 1.8–62.4 0.324 <0.001 0.199 <0.001
Thiosulfate, mmol/24 h 7 (4–12] 0–108 0.285 <0.001 0.170 <0.001
Creatinine, mmol/24 h 11.7 ± 3.4 2.9–23.3 0.397 <0.001 0.265 <0.001
Dietary intake c
Energy intake, kcal/24 h 2172 ± 619 658–4871 0.126 0.002 −0.038 0.34
Total protein intake, g/24 h 82 ± 12 26–144 0.190 <0.001 0.060 0.14
Animal protein intake, g/24 h 51 ± 13 18–110 0.133 0.001 0.085 0.03
Methionine intake, mg/24 h 1871 ± 327 687–3510 0.176 <0.001 0.077 0.05
Cysteine intake, mg/24 h 1187 ± 172 436–2296 0.238 <0.001 0.072 0.08
Meat intake, g/24 h 96 ± 38 0–275 0.223 <0.001 0.151 <0.001
Fish intake, g/24 h 11 (4–20) 0–134 0.104 0.01 0.096 0.008
Milk intake, g/24 h 117 ± 83 0–521 −0.005 0.90 0.016 0.66
Plant protein intake, g/24 h 31 ± 6 7–72 0.110 0.006 −0.077 0.06
Vegetable intake, g/24 h 93 ± 57 0–412 0.021 0.61 0.034 0.35
Fruit intake, g/24 h 152 ± 114 0–621 −0.117 0.004 −0.072 0.05
Total fat intake, g/24 h 88 ± 16 21–256 0.212 <0.001 −0.005 0.91
Saturated fat intake, g/24 h 31 ± 7 7–97 0.119 0.003 −0.021 0.59
Monounsaturated fat intake, g/24 h 30 ± 7 7–97 0.237 <0.001 0.016 0.72
Polyunsaturated fat intake, g/24 h 19 ± 6 4–74 0.151 <0.001 −0.026 0.52
Total carbohydrate intake, g/24 h 249 ± 63 16–537 0.186 <0.001 0.037 0.35
Mono and disaccharides intake, g/24 h 121 ± 34 9–301 0.106 0.008 −0.006 0.87
Polysaccharides intake, g/24 h 127 ± 28 8–297 0.190 <0.001 −0.009 0.83
Model 1: Crude, Model 2: Crude with adjustment for age, sex and eGFR. Urinary taurine excretion was log2-transformed for analysis. Regression coefficients are given as standardized
beta values (Std. β), the latter referring to the number of standard deviations a dependent variable changes per standard deviation increase of the independent variable, thereby allowing
for comparison of the strength of the associations of different variables. a Low alcohol intake was defined as 0–5 g/24 h in females, and 0–10 g/24 h in males. High alcohol intake was
defined as >5 g–24 h in females and >10 g–24 h in males). b For eGFR, model 2 was adjusted only for age and sex. c Dietary intake was adjusted for energy intake through the residual
method. Dietary intake range was shown for the unadjusted values. Abbreviations: BMI: body mass index; BSA: body surface area; CVA: cerebrovascular accident; TIA: transient ischemic
attack; HDL: high-density lipoprotein; LDL: low-density lipoprotein; HLA: human leukocyte antigen; eGFR: estimated glomerular filtration rate; hsCRP: high-sensitivity C-reactive protein.
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3.3. Dietary Intake
Univariate, urinary taurine excretion associated positively with the intake of energy (β = 0.126;
P = 0.002), total protein (β = 0.190; P < 0.001), animal protein (β = 0.133; P = 0.001), methionine
(β = 0.176; P< 0.001), cysteine (β= 0.238; P< 0.001), meat (β= 0.223; P< 0.001), fish (β= 0.104; P = 0.01),
plant protein (β = 0.110; P = 0.006), total fat (β = 0.212; P < 0.001) and total carbohydrate (β = 0.186;
P < 0.001). In contrast, urinary taurine was inversely associated with fruit intake (β = −0.117; P = 0.004).
After adjustment for age, sex and eGFR the associations of urinary taurine excretion with the intake
of energy, total protein, cysteine, plant protein, fruit, total fat and total carbohydrate disappeared
(All > 0.05), while the associations with animal protein intake (β = 0.085; P = 0.03), methionine intake
(β = 0.077; P = 0.05), meat intake (β = 0.151; P < 0.001) and fish intake (β = 0.096; P = 0.008) remained.
3.4. Graft Failure
During median follow-up for 5.3 (4.5–6.0) years, 83 (12%) patients developed graft failure. Patients
experiencing graft failure had almost two-fold lower urinary taurine excretion (320 (57–676) µmol/24
h versus 553 (239–964) µmol/24 h; P < 0.001), urinary taurine concentration (105 (30–290) µmol/L
versus 225 (101–430) µmol/L; P = 0.001) and urinary taurine/creatinine ratio (26 (7–58) µmol/mmol
versus 48 (22–82) µmol/mmol; P < 0.001) compared to patients not experiencing graft failure during
follow-up. Prospective analyses of the association between urinary taurine excretion, urinary taurine
concentration and urinary taurine/creatinine ratio with graft failure in RTR are shown in Table 2. In
Cox regression analyses, log2 transformed urinary taurine excretion (HR: 0.74 (0.67–0.082); P < 0.001),
urinary taurine concentration (HR: 0.75 (0.67–0.84); P < 0.001) and urinary taurine/creatinine ratio (HR:
0.74 (0.66–0.83); P < 0.001) were inversely associated with graft failure. After adjustment for relevant
covariates (age, sex, weight, height, eGFR and proteinuria) the associations of urinary taurine excretion
(HR: 0.83 (0.74–0.93); P = 0.002), urinary taurine concentration (HR: 0.84 (0.74–0.95); P = 0.007) and
urinary taurine/creatinine ratio (0.85 (0.75–0.96); P = 0.01) were somewhat weakened, but remained
significant. Further adjustment for cardiovascular risk factors (model 3), transplantation related factors
(model 4), polycystic kidney disease and urinary excretion of sodium, chloride, sulfate, thiosulfate and
creatinine (model 5) did not materially change the associations. No significant interactions terms were
found for the selected covariates (All P > 0.05). Analyses using creatinine clearance instead of eGFR
yielded similar results (Table S2). The optimal cutoff value (Youden index) of urinary taurine excretion
for prediction of graft failure was 285.4 µmol/24 h. At this cut off value, there was a sensitivity of 57%
and a specificity of 75% for prediction of graft failure. The associations of log2 transformed urinary
taurine excretion, urinary taurine concentration and urinary taurine/creatinine ratio as continuous
variables with death-censored graft failure are visualized in Figure 1.
Table 2. Association of urinary taurine excretion, urinary taurine concentration and urinary taurine
creatinine ratio with death-censored graft failure.
Model
Urinary Taurine Excretion Urinary Taurine Concentration Urinary Taurine/Creatinine Ratio
HR (95% CI) P Value HR (95% CI) P Value HR (95% CI) P Value
Model 1 0.74 (0.67–0.82) <0.001 0.75 (0.67–0.84) <0.001 0.74 (0.66–0.83) <0.001
Model 2 0.83 (0.74–0.93) 0.002 0.84 (0.74–0.95) 0.007 0.85 (0.75–0.96) 0.010
Model 3 0.82 (0.71–0.95) 0.01 0.83 (0.71–0.97) 0.02 0.84 (0.72–0.98) 0.03
Model 4 0.84 (0.74–0.95) 0.004 0.86 (0.76–0.98) 0.02 0.86 (0.76–0.98) 0.02
Model 5 0.84 (0.74–0.95) 0.006 0.84 (0.74–0.96) 0.01 0.84 (0.74–0.96) 0.01
Model 1. Log2-transformed urinary taurine excretion, urinary concentration or urinary taurine/creatinine ratio
(crude). Model 2. Model 1 + basic confounders (age, sex, weight, height, eGFR, proteinuria). Model 3. Model 2 +
cardiovascular risk factors (total cholesterol, HDL cholesterol, triglycerides, systolic blood pressure, antihypertensive
treatment, smoking (current, ex, or never), diabetes, medical history of coronary intervention, medical history of
myocardial infarction, medical history of CVA and/or TIA) and alcohol intake. Model 4. Model 2 + transplantation
related factors (donor type, total dialysis time, time between transplantation and baseline, cold ischemia time,
calcineurin inhibitor usage, proliferation inhibitor usage, and the number of transplantations up to baseline).
Model 5. Model 2 + polycystic kidney disease, urinary excretion of sodium, chloride, sulfate, thiosulfate and
creatinine. Abbreviations: HR: hazard ratio; CI: confidence interval; eGFR: estimated glomerular filtration rate;
HDL: high-density lipoprotein; CVA: cerebrovascular accident; TIA: transient ischemic attack.
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Figure 1. Continuous association of urinary taurine excretion (a), urinary taurine concentration (b) and urinary taurine/creatinine ratio (c) with death-censored graft failure. 
Urinary taurine excretion, urinary taurine concentration and urinary taurine/creatinine ratio were log2-transformed for prospective analysis. The histograms depict the 
distribution of urinary taurine excretion, urinary taurine concentration and urinary taurine/creatinine ratio. The black line shows the adjusted hazard ratio (HR) and the 
gray areas correspond to the 95% confidence interval (CI). The adjusted association was adjusted for age, sex, weight, height, eGFR and proteinuria. P values were 0.002, 
0.007 and 0.01, respectively.
Figure 1. Continuous association of urinary taurine excretion (a), urinary taurine concentration (b) and urinary taurine/creatinine ratio (c) with death-censored graft
failure. Urinary taurine excretion, urinary taurine concentration and urinary taurine/creatinine ratio were log2-transformed for prospective analysis. The histograms
depict the distribution of urinary taurine excretion, urinary taurine concentration and urinary taurine/creatinine ratio. The black line shows the adjusted hazard ratio
(HR) and the gray ar as correspond to the 95% confidence interval (CI). The adjusted association was adjusted for age, sex, weight, height, eGFR and proteinuria.
P values were 0.002, 0.007 and 0.01, respectively.
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4. Discussion
To the best of our knowledge, this is the first study that assessed urinary taurine excretion in
stable, outpatient RTR and investigated the prospective association of urinary taurine excretion with
late graft failure. Urinary taurine excretion did not differ between RTR and healthy controls and in
RTR urinary taurine excretion was positively associated with free serum sulfhydryl groups, but not
with high-sensitivity C-reactive protein. We found that high urinary taurine excretion associated with
lower risk of late graft failure in RTR, independent of potential confounders.
Despite the great impact of modern immunosuppression and anti-infection prophylaxis on
reducing acute graft failure, there has been little impact on long term graft survival [32]. A prelude
to most late graft failures is chronic renal dysfunction, which is believed to be a combination of both
immunological factors and non-immunological risk factors [33,34]. One of the non-immunological risk
factors thought to contribute to chronic renal dysfunction is oxidative stress [3,35–40], representing
damage to cells and tissues caused by reactive oxygen species (ROS). Compared to the general
population, biomarkers of oxidative stress are increased in renal transplant recipients [40] and are even
further increased in RTR with chronic transplant dysfunction [5]. In addition, in RTR, lower levels of
biomarkers of oxidative stress are associated with better outcome over time [4,39]. Possible sources of
these ROS in RTR could be inflammation [38,41,42], immunosuppressive drugs, e.g., ciclosporin [43,44],
and renal tissue hypoxia [3,45].
Taurine is a sulfonatedβ-amino acid, being present in very high concentrations in most mammalian
cells, comprising nearly 0.1% of the total body weight in humans [9,46]. Although taurine has been
shown to influence many physiological functions, its cytoprotective effects have gained the most
attention [7]. In humans, elevated taurine consumption is associated with decreased risk of hypertension
and hypercholesterolemia [47,48], reduced body mass index [49], and a reduction of inflammation
markers [50]. In our study, we did find a strong inverse association of urinary taurine excretion
with cholesterol and triglycerides, but no associations with blood pressure, body mass index or
high-sensitivity C-reactive protein. A possible reason that no association with blood pressure was
found in this study could be the high frequency of use of antihypertensive drugs in RTR. Median
urinary taurine excretion did not differ between RTR and healthy controls. Both the median urinary
taurine in RTR of 533 µmol/24 h and in healthy controls of 477 µmol/24 h were well in line with the
median urinary excretions reported for European, North American and Oceanic Caucasian participants
of the World Health Organization (WHO) Cardiovascular Diseases and Alimentary Comparison
(CARDIAC) study [51].
The mechanisms for the cytoprotective effects of taurine are not completely understood, but one
of the primary mechanisms appears to be its antioxidative properties. Several studies investigated the
scavenging activity of taurine in vitro and the results varied greatly. Concentrations ranging from 1
to 20 mM exhibited little to no scavenging activity against H2O2, superoxide anion radicals (O2•−),
or hydroxyl radicals (OH•) [52,53], while concentrations above 20 mM exhibited a concentration
dependent scavenging activity against peroxyl radicals (ROO•), nitric oxide (NO•), superoxide anion
radicals (O2•−) and peroxynitrite (ONOO−), with the greatest activity being achieved at a concentration
of 60 mM [54]. In vivo, extracellular taurine concentrations ranged from 10 to 100 µM and intracellular
concentrations ranged from 5 to 50 mM, with the highest intracellular concentrations found in
neutrophils and the retina [55].
A more universally accepted mechanism is that taurine diminishes superoxide in mitochondria
by conjugating with uridine of tRNALeu(UUR), which is supported by findings that promotors of
mitochondrial stress, such as ozone, bleomycin and catecholamines, respond favorably to taurine
supplementation [56,57]. Another mechanism is the attenuation of the toxicity of hypochlorous acid
(HOCl) produced by the myeloperoxidase (MPO) system in neutrophils. Taurine readily reacts with
hypochlorous acid to produce the more stable oxidant taurine chloramine [58–60]. Not only is taurine
chloramine less toxic, it also inhibits the production of inflammatory mediators, such as superoxide
anion, nitric oxide, tumor necrosis factor-α and interleukins 6, 8 and 12 [59–61]. Furthermore, in
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macrophages, taurine chloramine increases the expressions of several antioxidant proteins, such as
peroxiredoxin, thioredoxin, heme oxygenase 1 and glutathione peroxidase, partly via a Nrf2-dependent
signal transduction pathway [59–61]. Since neutrophils play an important role in both chronic rejection
and the resolution of inflammation [62], the mechanisms underlying the inverse association of urinary
taurine excretion and graft failure we observed may be a combination of both antioxidation and
anti-inflammatory effects. In our study, urinary taurine excretion was positively associated with free
sulfhydryl groups, indicating that patients with a higher urinary taurine excretion may have a more
favorable redox status [63–67]. Interestingly, we also found a strong association between urinary
taurine excretion and creatinine excretion. It is well known that 24 h urinary excretion of creatinine
is a reflection of muscle mass [68,69]. It has previously been suggested that taurine is a promising
nutritional agent to counteract the effects and development and sarcopenia [70]. While we cannot
determine a causal relation between urinary taurine excretion and creatinine excretion, it is clear that
this association is not mediated through a higher caloric intake, as there is no association of urinary
taurine excretion with energy intake. Adjustment for creatinine excretion in Cox-regression models
did not materially change the association of urinary taurine excretion with graft failure.
Though the antioxidative and anti-inflammatory effects of taurine have been extensively studied,
there are many other physiological functions that taurine fulfills. Taurine has been implicated in
energy metabolism, neuromodulation, Ca2+ homeostasis, attenuation of endoplasmic reticular stress,
osmoregulation [7], bile acid conjugation and maintenance of euglycemia [55]. Due to its wide variety of
effects, it is possible that some of the above-mentioned functions also play a role in the found association
with graft failure. In the Cox regression models, we adjusted for potential confounders, including age,
sex, body composition, renal function and proteinuria. The adjustments only caused slight weakening
of the association of urinary taurine excretion with graft failure, leaving a significant independent
association of urinary taurine excretion with graft failure. Further adjustment for cardiovascular risk
factors, transplantation related factors and urinary excretions did not materially affect the association.
Analysis of the optimal cut off value for urinary taurine excretion in predicting graft failure shows that
urinary taurine excretion does not perform very well if it would have been evaluated as a potential early
diagnostic tool for prediction of graft failure in RTR. The aim of our study was, however, to investigate
whether urinary taurine excretion might be a potential modifiable risk factor for the development of
graft failure in RTR. Our finding of a significant independent association of urinary taurine excretion
with graft failure suggests that this might indeed be the case.
In steady state, 24 h urinary excretion of taurine reflects a combination of dietary taurine intake
and endogenous taurine synthesis from cysteine. In the latter case, cysteine is first oxidized to cysteine
sulfinic acid, after which it can be further metabolized by two routes. Most cysteine sulfinic acid follows
the transamination route leading to the end-product sulfate. A smaller percentage is metabolized
to hypotaurine and eventually taurine. In humans, this endogenous synthesis of taurine is very
limited due to low activity of the rate limiting enzyme, cysteine sulfinic acid decarboxylase [9,11,55].
Consequently, dietary taurine uptake is the major supply of taurine. Important sources for taurine in
the human diet are seafood, poultry, beef and pork, processed meats and to a lesser degree dairy [11].
In contrast, plant-based foods contain little to no taurine [11]. Our data is consistent with this, as
urinary taurine excretion was associated with animal protein intake, meat intake and fish intake, but
not with fruit and vegetable intake. The association with animal protein intake may also underlie
strong associations of urinary taurine excretion with sulfate and thiosulfate excretion, which are both
end-products of the metabolism of sulfur containing amino acids [20].
After absorption, taurine is widely distributed among tissues, with the high concentrations found
in the retina, brain, heart, liver, kidney and muscles [55]. Plasma taurine is subsequently conjugated
with bile acids via its amine group or excreted unchanged in urine [9]. By varying taurine reabsorption,
the kidneys are the primary regulators of taurine homeostasis [9,71]. In humans, a study found that
95% of an intravenous injection of [35S] taurine was recovered in urine; about 70% in the form of
taurine and 25% in the form of sulfate [72]. After conjugation with bile acids and excretion in the
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gut, taurine is thought to be converted to inorganic sulfate by the intestinal microbiota, which is then
absorbed [72]. In human cells, it is unlikely that these reactions can take place and since taurine is also
not metabolized further, taurine is often considered chemically and biologically inert [46,72]. As the
kidneys are the primary regulators of taurine homeostasis and taurine is not metabolized further, a
higher 24 h urinary excretion may very well reflect a higher intake or absorption of taurine from the
gut. Indeed, studies have shown that urinary excretion of taurine is very low when dietary taurine
is restricted, as in a vegetarian diet. On the contrary, in diets with a higher taurine content, urinary
taurine excretion increases [71]. Therefore, an increased taurine intake may potentially improve graft
survival in renal transplant recipients.
Strengths of this study include the large sample size of this well-defined and specific patient
group of RTR, the long follow-up and the presence of appropriate controls. In addition, extensive data
collection of many demographical and laboratory parameters enabled adjustment for many potential
confounders. However, several limitations of this study need to be addressed. In general, statistical
significance in observational studies suggests, but does not confirm, biologic significance. Whether
the significant relation between urinary taurine excretion and graft failure in RTR is a causal or an
associative relation remains to be determined. Due to the observational design of this study we also
were unable to measure oxidative stress in the kidney, which precluded us from determining whether
urinary taurine excretion was associated with oxidative stress in the kidney. Similarly, the observational
design of this study does not allow for further studies to elucidate the biological mechanisms underlying
the association of urinary taurine excretion with graft failure. Furthermore, the observational design of
the study precluded us to demonstrate in an experimental way that urinary taurine excretion is not
influenced by renal function. In addition, our study population consisted predominantly of Caucasian
individuals, which calls prudence to extrapolation of our results to populations of other ethnicities.
Lastly, the Dutch Food Composition Table did not include information on taurine content, which
prevented us from comparing FFQ-based taurine intake to urinary excretion of taurine.
5. Conclusions
Higher urinary taurine excretion is associated with improved graft survival in renal transplant
recipients. As taurine synthesis in humans is very limited, 24 h urinary taurine excretion largely
reflects daily taurine intake. Therefore, an increased taurine intake may potentially increase graft
survival in renal transplant recipients. However, further research is warranted to determine the
mechanisms underlying this association and to investigate the potential of taurine supplementation in
renal transplant recipients.
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